Mission

The mission of SyneuRx is to use a humanistic approach to bring breakthrough therapeutics to diseases and conditions where there are significant unmet needs.

Philosophy

Value-Based

We aim to develop breakthrough therapies that bring the forefront of science to patients with real, meaningful value rather than focusing on drugs that yield limited marginal benefits.

Screen Shot 2022-07-09 at 7.57.46 PM
Safety-First

We screen and select potential compounds based on safety-first. This is particularly important for the central nervous system (CNS) pipeline due to the widespread presence of NMDA receptors in the brain and the potential neurotoxicity that misfit compounds can induce.

Human-Health Focus

We aspire to promote human health in addition to improving patient health individually. The development of potential treatment for schizophrenia, dementia and depression can contribute to mental health parity. SyneuRx will make all potential new treatments available worldwide, eliminating inequity in health due to access. 

We pledge to minimize the environmental impacts in all steps of our research and development and commercialization process, including green sourcing and manufacturing, minimizing toxic wastes and green disposal.

We strive to promote a people-centric work environment that focuses on how our employees work best and provides them with inspiration and motivation to do their work.

“To properly address the challenges of mental health today, healthcare providers, government leaders and passionate experts must come together. Community-based social support services, that honors whole-person needs and improves outcomes, and that brings together robust, cross-sector collaboration – public, private, academic, faith-based and others – to co-create community-wide mental health and wellness options for all residents is how behavioral health needs in this country must be met.”

Emil Tsai, CEO

Leadership Team

“Questioning old assumptions is the true spirit of science.”

“Science meets humanity in the journey of SyneuRx’s drug discovery.”

“The best science is what your grandmother can understand.”

“Syneurx will be successful driven by its solid science, evidence-based data, and patient-centered innovation.”
“Together, We Go Far!”
“SyneuRx has a solid scientific foundation that a biotechnology company needs for the success.”
“Our aim is to create new chances to the wholeness of human beings, both physically and mentally.”
“Do our best and make the world better!”
“Looking forward to providing great benefit to patients with mental health problems.”

“Innovate with joy for a healthier world.”

“I wish Syneurx will become an important source of contribution to the welfare of mankind in the world.”

Major Milestones

May, 2022

May, 2022

COVID MOA results published in ACS.

April, 2022

April, 2022

Pentarlandir® Phase 2 reached target enrollment.

Auguest, 2021

Auguest, 2021

Phase II study Pentarlandir® (SNB011) for early and mild COVID-19 was initiated in the US.

March, 2021

March, 2021

Phase 2 IND of Synxyrin® (SNA11) for treatment-resistant depression and suicidal symptoms was approved by the US FDA.

September, 2019

September, 2019

Phase 2 IND of Tannquilynne® (SND51) for dementia with psychosis was approved by the US FDA.

May, 2018

May, 2018

Phase 3 IND of Synapsinae® (SNG12) for major depressive disorder and suicidal symptoms was approved by the US FDA.

March, 2017

March, 2017

Phase 2b/3 clinical studies (SND12 & SND13) of NaBen for refractory schizophrenia and adult schizophrenia were initiated.

April, 2016

April, 2016

Phase 2b/3 IND of NaBen® (SND14) for mild dementia was approved by the US FDA.

January, 2016

January, 2016

SyneuRx was listed in the Emerging Board of Taipei Stock Exchange under the ticker of “TT6575”.

November, 2015

November, 2015

Breakthrough Therapy Designation for ClozaBen®(SND12) in refractory schizophrenia was granted by the US FDA.

December, 2014

December, 2014

Breakthrough Therapy Designation for NaBen®(SND13) in adult schizophrenia was granted by the US FDA.

June, 2014

June, 2014

Phase 2b/3 study (SND11) of NaBen for adolescent schizophrenia was initiated in the US.

2013 Company Founded

SyneuRx was founded by Emil Tsai, MD, PhD, MAS,
UCLA Professor in Psychiatry.